Literature DB >> 30386930

Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

John P M Finberg1.   

Abstract

MAO-B and COMT are both enzymes involved in dopamine breakdown and metabolism. Inhibitors of these enzymes are used in the treatment of Parkinson's disease. This review article describes the scientific background to the localization and function of the enzymes, the physiological changes resulting from their inhibition, and the basic and clinical pharmacology of the various inhibitors and their role in treatment of Parkinson's disease.

Entities:  

Keywords:  COMT; Dopamine synthesis; Dyskinesia; L-DOPA; MAO-B

Mesh：

Substances：

Year:  2018        PMID： 30386930     DOI： 10.1007/s00702-018-1952-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  145 in total

Review 1.  Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease.

Authors:  M A Cenci; K E Ohlin; P Odin
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

2.  Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.

Authors:  Miho Murata; Kazuko Hasegawa; Ichiro Kanazawa
Journal:  Neurology       Date:  2007-01-02       Impact factor: 9.910

3.  Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.

Authors:  S P Butcher; I S Fairbrother; J S Kelly; G W Arbuthnott
Journal:  J Neurochem       Date:  1990-09       Impact factor: 5.372

Review 4.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

Review 5.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

Review 6.  The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.

Authors:  Orit Bar-Am; Orly Weinreb; Tamar Amit; Moussa B H Youdim
Journal:  J Neurochem       Date:  2009-12-10       Impact factor: 5.372

7.  The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl.

Authors:  J Knoll
Journal:  Mech Ageing Dev       Date:  1988-12       Impact factor: 5.432

8.  A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.

Authors:  J J Mann; S F Aarons; P J Wilner; J G Keilp; J A Sweeney; T Pearlstein; A J Frances; J H Kocsis; R P Brown
Journal:  Arch Gen Psychiatry       Date:  1989-01

Review 9.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Authors:  David S Goldstein; Irwin J Kopin; Yehonatan Sharabi
Journal:  Pharmacol Ther       Date:  2014-06-16       Impact factor: 12.310

10.  Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.

Authors:  Miho Murata; Toshinari Odawara; Kazuko Hasegawa; Sayaka Iiyama; Masatoshi Nakamura; Masaaki Tagawa; Kenji Kosaka
Journal:  Neurology       Date:  2018-01-24       Impact factor: 9.910
View more
  11 in total

1.  Is impaired dopaminergic function associated with mobility capacity in older adults?

Authors:  Simon Moskowitz; David W Russ; Leatha A Clark; Nathan P Wages; Dustin R Grooms; Adam J Woods; Julie Suhr; Janet E Simon; Andrew O'Shea; Cody R Criss; Paolo Fadda; Brian C Clark
Journal:  Geroscience       Date:  2020-11-24       Impact factor: 7.713

2.  Protein lifetimes in aged brains reveal a proteostatic adaptation linking physiological aging to neurodegeneration.

Authors:  Verena Kluever; Belisa Russo; Sunit Mandad; Nisha Hemandhar Kumar; Mihai Alevra; Alessandro Ori; Silvio O Rizzoli; Henning Urlaub; Anja Schneider; Eugenio F Fornasiero
Journal:  Sci Adv       Date:  2022-05-20       Impact factor: 14.957

3.  Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone.

Authors:  Joe Yamamoto; Tomohiro Omura; Sachiko Kasamo; Shota Yamamoto; Masayoshi Kawata; Atsushi Yonezawa; Yosuke Taruno; Hisako Endo; Hitoshi Aizawa; Nobukatsu Sawamoto; Kazuo Matsubara; Ryosuke Takahashi; Yoshikazu Tasaki
Journal:  J Neural Transm (Vienna)       Date:  2020-11-02       Impact factor: 3.575

Review 4.  Physical Activity and Brain Health.

Authors:  Carlo Maria Di Liegro; Gabriella Schiera; Patrizia Proia; Italia Di Liegro
Journal:  Genes (Basel)       Date:  2019-09-17       Impact factor: 4.096

Review 5.  Dopamine in Health and Disease: Much More Than a Neurotransmitter.

Authors:  Rafael Franco; Irene Reyes-Resina; Gemma Navarro
Journal:  Biomedicines       Date:  2021-01-22

Review 6.  Potentiating the Benefits of Melatonin through Chemical Functionalization: Possible Impact on Multifactorial Neurodegenerative Disorders.

Authors:  Annia Galano; Eduardo G Guzmán-López; Russel J Reiter
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

Review 7.  Chalcones as Potential Ligands for the Treatment of Parkinson's Disease.

Authors:  Ewelina Królicka; Katarzyna Kieć-Kononowicz; Dorota Łażewska
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-10

Review 8.  Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease.

Authors:  Jing Liu; Fei Xu; Zhiyan Nie; Lei Shao
Journal:  Front Cell Infect Microbiol       Date:  2020-10-22       Impact factor: 5.293

9.  Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis.

Authors:  Hyun-U Cho; Sunpil Kim; Jeongeun Sim; Seulkee Yang; Heeyoung An; Min-Ho Nam; Dong-Pyo Jang; C Justin Lee
Journal:  Exp Mol Med       Date:  2021-07-09       Impact factor: 12.153

Review 10.  Mechanistic Insights Expatiating the Redox-Active-Metal-Mediated Neuronal Degeneration in Parkinson's Disease.

Authors:  Tapan Behl; Piyush Madaan; Aayush Sehgal; Sukhbir Singh; Md Khalid Anwer; Hafiz A Makeen; Mohammed Albratty; Syam Mohan; Simona Bungau
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.